Benicar Sales Aid Draws FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency objects to superiority and efficacy claims for the Forest/Sankyo angiotension II receptor blocker based on misleading comparisons and inadequate studies.